Piper Sandler Forecasts Strong Price Appreciation for Kenvue (NYSE:KVUE) Stock

Kenvue (NYSE:KVUE) had its target price hoisted by equities researchers at Piper Sandler from $24.00 to $27.00 in a research note issued on Monday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Piper Sandler’s price objective would suggest a potential upside of 15.51% from the stock’s current price.

Several other analysts have also issued reports on KVUE. Barclays cut their price target on shares of Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a research report on Friday, January 17th. Canaccord Genuity Group dropped their price target on shares of Kenvue from $27.00 to $24.00 and set a “buy” rating on the stock in a research note on Friday, February 7th. Citigroup decreased their price objective on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating for the company in a report on Wednesday, January 15th. Deutsche Bank Aktiengesellschaft cut shares of Kenvue from a “buy” rating to a “hold” rating and dropped their price target for the stock from $25.00 to $24.00 in a research note on Thursday, December 12th. Finally, Royal Bank of Canada reissued a “sector perform” rating and set a $24.00 price target on shares of Kenvue in a report on Monday, February 3rd. One analyst has rated the stock with a sell rating, eight have given a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, Kenvue currently has a consensus rating of “Hold” and an average target price of $23.08.

Kenvue Price Performance

Shares of NYSE KVUE opened at $23.38 on Monday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The stock has a market cap of $44.82 billion, a PE ratio of 44.10, a price-to-earnings-growth ratio of 2.62 and a beta of 1.45. Kenvue has a fifty-two week low of $17.67 and a fifty-two week high of $24.46. The stock has a fifty day moving average of $21.33 and a 200-day moving average of $22.21.

Kenvue (NYSE:KVUE) last issued its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. Equities research analysts anticipate that Kenvue will post 1.14 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in KVUE. Grove Bank & Trust increased its position in Kenvue by 438.4% during the 4th quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock valued at $25,000 after purchasing an additional 947 shares during the period. Geneos Wealth Management Inc. purchased a new position in shares of Kenvue in the fourth quarter worth $29,000. SRS Capital Advisors Inc. grew its stake in Kenvue by 67.4% during the 4th quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company’s stock valued at $30,000 after purchasing an additional 571 shares during the last quarter. Fortitude Family Office LLC raised its position in Kenvue by 106.6% during the 4th quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock worth $32,000 after buying an additional 777 shares during the last quarter. Finally, Ashton Thomas Securities LLC purchased a new stake in shares of Kenvue in the 3rd quarter valued at $35,000. 97.64% of the stock is currently owned by institutional investors.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.